Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate

European Neurology

Volumn 65, Issue 4, 2011, Pages 231-232

  Yildiz, Murat ^a   Tettenborn, Barbara ^a   Putzki, Norman ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

BLOOD BRAIN BARRIER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FATIGUE; FATIGUE SEVERITY SCALE; HUMAN; LETTER; LEUKOCYTE MIGRATION; MODIFIED FATIGUE IMPACT SCALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PREVALENCE;

EID: 79953185078     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324028     Document Type: Letter

References (10)

1. Fisk JD, Pontrefact A, Ritvo PG, et al: The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994; 21: 9-14. (Pubitemid 24090744)
2. Heesen C, Nawrath L, Reich C, et al: Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psych 2006; 77: 34-39. (Pubitemid 43022687)
3. Putzki N, Katsarava Z, Vago S, et al: Prevalence and severity of multiple sclerosis associated fatigue. Eur Neurol 2008; 59: 136-142.
4. Polman CH, O'Connor PW, Havrdova E, et al: A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
5. Bergamaschi R, Romani A, Versino M, et al: Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 1997; 12: 247-251. (Pubitemid 28023053)
6. Krupp LB, LaRocca NG, Muir-Nash J, et al: The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123. (Pubitemid 19246303)
7. Colosimo C, Millefiorini E, Grasso MG, et al: Fatigue in MS is associated with specific clinical feature. Acta Neurol Scand 1995; 92: 353-355.
8. Flachenecker P, Kümpfel T, Kallmann B, et al: Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameter. Mult Scler 2002; 8: 523-526. (Pubitemid 35396404)
9. Metz LM, Patten SB, Archibald CJ, et al: The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psych 2004; 75: 1045-1047. (Pubitemid 38869624)
10. Putzki N, Yaldizli Ö, Tettenborn B, et al: Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sc 2009; 285: 109-113.